AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9350488 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy and videonasopharyngoscopy as an instrument for visual biofeedback of the velopharyngeal sphincter
Number of subjects: 17
Study 9350488 — intervention group
Group type: COMPARATOR
Intervention: Speech therapy only
Number of subjects: 17
Study 9350488 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (including both groups)
Number of subjects: 17
Study 9350488 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback postoperatively
Number of subjects: 17
Study 8456422 — intervention group
Group type: EXPERIMENTAL
Intervention: factor VIII‐P, an intermediate purity pasteurized concentrate
Number of subjects: 218
Study 8456422 — intervention group
Group type: COMPARATOR
Intervention: factor VIII‐SD, a high purity concentrate treated with solvent‐detergent
Number of subjects: 218
Study 3529362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg, given twice daily for 2 days
Number of subjects: 20
Study 3529362 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given twice daily for 2 days
Number of subjects: 20
Study 3529362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 20
Study 30563582 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine maintenance
Number of subjects: 0
Study 30563582 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term continuous antipsychotic treatment
Number of subjects: 0
Study 30563582 — intervention group
Group type: COMPARATOR
Intervention: Non-users of antipsychotics
Number of subjects: 0
Study 30563582 — intervention group
Group type: COMPARATOR
Intervention: Discontinued treatment
Number of subjects: 0
Study 28662260 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 52
Study 28662260 — intervention group
Group type: COMPARATOR
Intervention: No meditation (Control)
Number of subjects: 52
Study 26044556 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 428
Study 23541105 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMED FitMate™ metabolic system
Number of subjects: 30
Study 23541105 — intervention group
Group type: COMPARATOR
Intervention: COSMED QUARK CPET research-based system
Number of subjects: 30
Study 22071059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 L of oxygen by nonrebreather mask during and for 2 hours after cesarean delivery
Number of subjects: 585
Study 22071059 — intervention group
Group type: COMPARATOR
Intervention: 2 L of oxygen by nasal cannula during cesarean delivery only (standard care)
Number of subjects: 585
Study 19575268 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge summaries
Number of subjects: 696
Study 19575268 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up providers' information
Number of subjects: 696
Study 17053333 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT)
Number of subjects: 111
Study 17053333 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 111
Study 15485007 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 102
Study 11257644 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 40
Study 11257644 — intervention group
Group type: COMPARATOR
Intervention: Ureteral stents
Number of subjects: 40
Study 9155286 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed psychological preparation and support
Number of subjects: 48
Study 9155286 — intervention group
Group type: COMPARATOR
Intervention: Standard informal preparation
Number of subjects: 48
Study 7960973 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment including a new 'opponens roll' maneuver and self-stretching
Number of subjects: 20
Study 7960973 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment appliance
Number of subjects: 20
Study 7960973 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal, symptom-free subjects)
Number of subjects: 20
Study 3068344 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (30‐90 mg twice a day)
Number of subjects: 295
Study 3068344 — intervention group
Group type: COMPARATOR
Intervention: Captopril (12.5‐50 mg twice a day)
Number of subjects: 295
Study 29679723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction group (LR group, n=31)
Number of subjects: 62
Study 29679723 — intervention group
Group type: COMPARATOR
Intervention: Single hook plate group (HP group, n=31)
Number of subjects: 62
Study 25790834 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stabilization training
Number of subjects: 31
Study 25790834 — intervention group
Group type: COMPARATOR
Intervention: Standard training (stretching and quadriceps strengthening)
Number of subjects: 31
Study 23458227 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Control condition (no rhinitis)
Number of subjects: 54
Study 23458227 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Rhinitis condition (symptomatic without decongestant)
Number of subjects: 54
Study 23458227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS) 100 μg under Treated condition (symptomatic with oxymetazoline)
Number of subjects: 54
Study 21593499 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 μg folic acid/d
Number of subjects: 144
Study 21593499 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg folic acid/d
Number of subjects: 144
Study 21593499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 19564636 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC)
Number of subjects: 110
Study 19564636 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (SC) alone
Number of subjects: 110
Study 19564636 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythroid responders
Number of subjects: 110
Study 19564636 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis
Number of subjects: 110
Study 16221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker frequencies in the delta band (2-4 Hz) and upper alpha band (10-11 Hz)
Number of subjects: 15
Study 16221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker frequencies in the lower alpha band (8-10 Hz)
Number of subjects: 15
Study 16221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to peripheral flicker
Number of subjects: 15
Study 16221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed away from flicker to foveal stimuli
Number of subjects: 15
Study 15530271 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle
Number of subjects: 100
Study 15530271 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Whitacre needle
Number of subjects: 100
Study 11125533 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory model presented at 100% frequency
Number of subjects: 45
Study 11125533 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory model presented at 50% frequency
Number of subjects: 45
Study 11125533 — intervention group
Group type: COMPARATOR
Intervention: No auditory model (0% frequency)
Number of subjects: 45
Study 9262932 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 1052
Study 9262932 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant-II
Number of subjects: 1052
Study 7506020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% alone (n = 14)
Number of subjects: 46
Study 7506020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with dextran 70 (n = 16)
Number of subjects: 46
Study 7506020 — intervention group
Group type: COMPARATOR
Intervention: Saline control (n = 16)
Number of subjects: 46
Study 3674849 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 187
Study 3674849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 187
Study 3674849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 187
Study 3674849 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 187
Study 3674849 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside serum levels, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence of bacteremia, shock, liver cirrhosis, dehydration, previous otic pathology or renal failure, and development of renal toxicity
Number of subjects: 187
Study 28841229 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU orally 12 hours before PCI)
Number of subjects: 99
Study 28841229 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D)
Number of subjects: 99
Study 26983946 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for 6 months
Number of subjects: 303
Study 26983946 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 6 months
Number of subjects: 303
Study 24211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 540
Study 24211508 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 540
Study 23739521 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping of the face, mouth, and nose with a towel (wipe group)
Number of subjects: 488
Study 23739521 — intervention group
Group type: COMPARATOR
Intervention: Oronasopharyngeal suction with a bulb syringe (suction group)
Number of subjects: 488
Study 20022872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells (BMSCs) administered into infarct-related artery (IRA) at 4-6 days after primary PCI
Number of subjects: 45
Study 20022872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells (BMSCs)
Number of subjects: 45
Study 20022872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 19128603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation for 3 months
Number of subjects: 77
Study 19128603 — intervention group
Group type: COMPARATOR
Intervention: Nonirrigation
Number of subjects: 77
Study 21876511 — intervention group
Group type: EXPERIMENTAL
Intervention: Provinols™ (4 mg/kg of body weight)
Number of subjects: 0
Study 21876511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21876511 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 16199636 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 110
Study 16199636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 110
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 25% MVC
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 50% MVC
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 75% MVC
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at increasing intensities
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions at increasing intensities
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at 100% MVC
Number of subjects: 10
Study 11811575 — intervention group
Group type: EXPERIMENTAL
Intervention: All contraction modes at increasing intensities
Number of subjects: 10
Study 9812110 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent procedure with structured and rigorous explanation
Number of subjects: 49
Study 7720893 — intervention group
Group type: EXPERIMENTAL
Intervention: jet-cutter
Number of subjects: 116
Study 7720893 — intervention group
Group type: COMPARATOR
Intervention: blunt dissection
Number of subjects: 116
Study 7720893 — intervention group
Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 116
Study 2503147 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight for age
Number of subjects: 1011
Study 2503147 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in weight
Number of subjects: 1011
Study 2503147 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth monitoring
Number of subjects: 1011
Study 774004 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with various amounts of caffeine
Number of subjects: 12
Study 774004 — intervention group
Group type: COMPARATOR
Intervention: Uncaffeinated liquid (placebo)
Number of subjects: 12
Study 11800181 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control training procedure with reinforcer immediacy competing with another influential dimension (e.g., RvI or QvI)
Number of subjects: 3
Study 11800181 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control training procedure
Number of subjects: 3
Study 11800181 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of reinforcer dimensions (R, Q, I, E)
Number of subjects: 3
Study 31540607 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 789
Study 31540607 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 789
Study 28946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 549
Study 28946761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 27875540 — intervention group
Group type: EXPERIMENTAL
Intervention: non-symbolic training
Number of subjects: 56
Study 27875540 — intervention group
Group type: EXPERIMENTAL
Intervention: symbolic training
Number of subjects: 56
Study 27875540 — intervention group
Group type: COMPARATOR
Intervention: control training
Number of subjects: 56
Study 25416514 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Coaching (small-group face-to-face contact during inpatient rehabilitation, telephone aftercare, internet-based aftercare)
Number of subjects: 412
Study 25416514 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (not specified in detail)
Number of subjects: 412
Study 23043578 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide (75-100 mg/m²) followed by six cycles of adjuvant high-dose temozolomide (150-200 mg/m²)
Number of subjects: 68
Study 23043578 — intervention group
Group type: COMPARATOR
Intervention: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide
Number of subjects: 68
Study 21921460 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (200 mg/day)
Number of subjects: 2672
Study 21921460 — intervention group
Group type: COMPARATOR
Intervention: aspirin (81 mg/day)
Number of subjects: 2672
Study 17196908 — intervention group
Group type: EXPERIMENTAL
Intervention: Only ATC opioid
Number of subjects: 174
Study 17196908 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC+PRN opioid
Number of subjects: 174
Study 17196908 — intervention group
Group type: COMPARATOR
Intervention: Only PRN opioid
Number of subjects: 174
Study 17196908 — intervention group
Group type: COMPARATOR
Intervention: No opioid
Number of subjects: 174
Study 15663612 — intervention group
Group type: EXPERIMENTAL
Intervention: iVPA 800 mg
Number of subjects: 40
Study 15663612 — intervention group
Group type: COMPARATOR
Intervention: iLAS 1000 mg
Number of subjects: 40
Study 12603080 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine load (20 g in 100 mL tap water)
Number of subjects: 18
Study 12603080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL tap water)
Number of subjects: 18
Study 12603080 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine load
Number of subjects: 18
Study 12603080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10585037 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) and blood donation (group 1)
Number of subjects: 32
Study 10585037 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation alone (group 2)
Number of subjects: 32
Study 8729587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day and bezafibrate 400 mg/day
Number of subjects: 38
Study 8729587 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin and cholestyramine
Number of subjects: 38
Study 8729587 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin as monotherapy
Number of subjects: 38
Study 8729587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin and bezafibrate
Number of subjects: 38
Study 1816189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g
Number of subjects: 5
Study 1816189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g
Number of subjects: 5
Study 1816189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g
Number of subjects: 5
Study 7049710 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 100 mg
Number of subjects: 32
Study 7049710 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorthalidone 10 mg
Number of subjects: 32
Study 7049710 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 100 mg and chlorthalidone 10 mg combined
Number of subjects: 32
Study 31668592 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally once daily for 12 weeks
Number of subjects: 977
Study 31668592 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once daily for 12 weeks
Number of subjects: 977
Study 31668592 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 977
Study 31668592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977
Study 28814161 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ART
Number of subjects: 79
Study 28814161 — intervention group
Group type: COMPARATOR
Intervention: First-line ART
Number of subjects: 79
Study 26094849 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation along a fictitious field (RAFF)
Number of subjects: 50
Study 26094849 — intervention group
Group type: COMPARATOR
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 50
Study 26094849 — intervention group
Group type: COMPARATOR
Intervention: T2 mapping
Number of subjects: 50
Study 24859111 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0
Study 24859111 — intervention group
Group type: COMPARATOR
Intervention: Fecal Immunochemical Testing (FIT)
Number of subjects: 0
Study 22166255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive tight control therapy including adalimumab (n=42), with a protocol aimed for remission (DAS < 1.6).
Number of subjects: 82
Study 22166255 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n=40) with traditional DMARDs (no prednisone or biologics).
Number of subjects: 82
Study 20507035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0
Study 20507035 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17656182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 405
Study 17656182 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable applicators
Number of subjects: 405
Study 17656182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm
Number of subjects: 405
Study 17656182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 405
Study 16306499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of salbutamol and fluticasone
Number of subjects: 9
Study 16306499 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 9
Study 11887180 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP gene mutation analysis using RT-PCR
Number of subjects: 225
Study 11887180 — intervention group
Group type: COMPARATOR
Intervention: D442G allelic frequency analysis
Number of subjects: 225
Study 12382595 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic PM task of logging the time at four set times for one week with varying complexity of the time schedule
Number of subjects: 380
Study 12382595 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective memory tasks and event-based and time-based laboratory PM tasks
Number of subjects: 380
Study 7890078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline-treated semen
Number of subjects: 97
Study 7890078 — intervention group
Group type: COMPARATOR
Intervention: Control semen
Number of subjects: 97
Study 2784172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined operations (IIA; n = 71)
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: CAB followed by delayed CE (IIB; n = 58)
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Delayed CE performed within 2 weeks after CAB
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Delayed CE with longer staging intervals
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Preliminary or simultaneous CE
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Delayed CE only
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Group I (stable cardiac disease)
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Group II (unstable disease)
Number of subjects: 275
Study 2784172 — intervention group
Group type: COMPARATOR
Intervention: Group III (symptomatic or bilateral carotid stenosis)
Number of subjects: 275
Study 305728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dipivalyl epinephrine (DPE)
Number of subjects: 0
Study 305728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% dipivalyl epinephrine (DPE)
Number of subjects: 0
Study 305728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% dipivalyl epinephrine (DPE)
Number of subjects: 0
Study 305728 — intervention group
Group type: COMPARATOR
Intervention: 1% epinephrine hydrochloride
Number of subjects: 0
Study 30782070 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 150
Study 30782070 — intervention group
Group type: COMPARATOR
Intervention: Structured telephone support
Number of subjects: 150